A Study of LY3127804 With Ramucirumab in Participants With Advanced Solid Tumors

Inclusion Criteria:

• Have a diagnosis of cancer that is advanced and/or metastatic.
• Have disease as defined by the Response Evaluation Criteria in Solid Tumors (RECIST ) version 1.1.
• Have adequate organ function.
• Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
• Have discontinued previous treatments for cancer for at least 28 days or 5 half-lives prior to study enrolment.

Exclusion Criteria:

• Have serious preexisting medical conditions.
• Have received treatment with a drug predominantly targeting Ang2 activity.
• Have symptomatic central nervous system (CNS) malignancy or metastasis.
• Have current hematologic malignancies.
• Have an active fungal, bacterial, and/or known viral infection.
• Have a corrected QT interval using Fridericia's correction (QTcF) of >470 msec on screening electrocardiogram (ECG) at several consecutive days of assessment.
• Have a known sensitivity to mAbs or other therapeutic proteins.
• Have a history of hypertensive crisis or hypertensive encephalopathy or current poorly controlled hypertension despite standard medical management.
• Have a significant bleeding disorder or vasculitis or had a Grade ≥3 bleeding episode within 3 months prior to receiving treatment.
• Receive anticoagulation therapy at therapeutic dose.
• Have experienced any arterial or venothrombotic or thromboembolic events within 6 months prior to study treatment.
• Have liver cirrhosis with a Child-Pugh class B or worse or cirrhosis (any degree) and a history of hepatic encephalopathy or clinically meaningful ascites resulting from cirrhosis.
• The participant is pregnant prior to randomization or breastfeeding.
• The participant has sensory peripheral neuropathy ≥ Grade 2 (Part E only).